Alessandro Musso

Fondazione Ricerca Molinette

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Alessandro Repici

IRCCS Humanitas Research Hospital

Giorgio Maria Saracco

University of Turin

C. Barletti

University of Turin

Claudio De Angelis

Paul Scherrer Institute

P. Carucci

University of Turin

M. Rizzetto

University of Turin

S. Caronna

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Franco Radaelli

Ospedale Valduce

Cesare Hassan

Humanitas University

Lorenzo Fuccio

Azienda USL di Bologna

Cooperative Institutions

University of Turin

116

Azienda Ospedaliero Universitaria San Giovanni Battista

Fondazione Ricerca Molinette

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Istituti di Ricovero e Cura a Carattere Scientifico

University of Bologna

Ospedale Maggiore

Piedmont Reference Center for Epidemiology and Cancer Prevention

Cleveland Clinic

University of Milan

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Lower esophageal sphincter (les) augmentation therapy for GERD with enteryx™, a biocompatible inert polymer. Initial multicenter human trial results

Gastrointestinal Endoscopy (2001)

Alessandro Repici S. Paganin C. Barletti Claudio De Angelis S. Caronna

Esophageal sphincter

Biocompatible material

Multicenter trial

10.1016/s0016-5107(01)80235-2

Cite

Citations (2)

Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.

PubMed (1980)

F Cavagnaro J M Lein S Pavlovsky J O Becherini Juan Pileggi

Of 139 evaluable and previously untreated patients with multiple myeloma, 67 received methyl-CCNU-cyclophosphamide-prednisone (group A) and 72 received melphalan-prednisone (group B); 48% and 33% respectively had good responses and the overall response rates (good plus partial) were 75% and 65% for groups A and B respectively. The survival curves for both groups of patients were similar, with a median survival of 32 months. At 36 months, 70% of those patients who obtained good response were alive, 29% of those with partial response were alive, and 13% of those with no response were alive. The clinical staging system described by Durie and Salmon shows a good prognosis for stage I patients, with 80% remaining alive at 48 months, while the survival curves for stage II and III patients were similar, with 33% and 28% respectively remaining alive at 48 months. The combination of methyl-CCNU-cyclophosphamide-prednisone is not more effective in terms of response rate or duration of survival than melphalan-prednisone.

Melphalan

Nitrogen mustard

Source

Cite

Citations (22)

Sa1035 Periendoscopic Management of Direct Oral Anticoagulants: A Prospective Cohort Study

Gastrointestinal Endoscopy (2017)

Franco Radaelli Lorenzo Fuccio Silvia Paggi Milena Di Leo Cristina Trovato

Discontinuation

Clinical Practice

10.1016/j.gie.2017.03.354

Cite